Medivation’s Dimebon(TM) Significantly Improved Thinking And Memory In Alzheimer’s Disease Patients Over One Year
Apr 22nd 2008Drug InformationAlzheimer's / Dementia News XML/RSS Feed
Medivation, Inc. (NASDAQ: MDVN) has announced that Alzheimer’s patients treated with the investigational drug Dimebon? showed improvement in the key aspects of cognitive function over a one-year period compared with placebo. The improvement occurred in not only memory and language, but also in more complex functions such as awareness of time and place, and praxis - the process of getting an idea and initiating and completing a new motor task.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
